Morrisville, North Carolina-based kSep has developed and markets single-use, fully automated centrifugation systems used for manufacturing biopharmaceuticals, such as vaccines, cell-based therapeutics and monoclonal antibodies.

kSep is expected to have sales revenues of US$7 million in 2016.
 
The transaction, which values kSep at around US$28 million, is expected to close by the end of July 2016.
 
Reinhard Vogt, a member of Sartorius Stedim Biotech’s board, said: “kSep’s centrifuges are a very innovative, single-use cell separation technology that perfectly complements our offering for downstream bioprocessing. Our clients will greatly benefit from the unique ability to collect, wash and concentrate cells quickly and reduce both the time and cost of downstream purification steps.”
 
“Sartorius Stedim Biotech’s strong relationships with its customers will significantly speed up our internationalization and business growth. SSB will provide access to considerably more customers, especially in Asia, a market we haven’t developed yet,” said Sunil Mehta, president and CEO of kSep.
 
Sartorius Stedim Biotech will retain kSep’s current leadership and staff.